www.hivandhepatitis.com

Back HCV Treatment

EASL 2015: Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis

Details
Category: HCV Treatment
Published on Wednesday, 06 May 2015 00:00
Written by Liz Highleyman
  • Print

Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of genotype 1 chronic hepatitis C patients with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. The sustained response rate in HCV-TARGET fell to 39% for genotype 3, but another study found that 70% of genotype 3 patients with decompensated cirrhosis could be cured with sofosbuvir plus daclatasvir (Daklinza), while sofosbuvir/ledipasvir (Harvoni) cured up to 86% of genotype 1 patients.

alt

Read more:

Subcategories

Copyright © 2026 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design